益气活血是中医治疗心脑血管血栓性疾病的常用治法，抗血栓形成同时减少出血风险是心脑血管血栓性疾病治疗的主要目的。益气活血中药配伍联合双抗血小板药物（阿司匹林、氯吡格雷），是否可进一步加强抗血栓形成作用，同时减少出血风险，目前尚缺少研究报道。针对这一问题，本项目通过大鼠颈动脉血栓模型（局部脑缺血模型）、大鼠心肌梗死模型、脂质过氧化和血小板活化致内皮损伤模型，观察益气活血配伍联合双抗抗血栓形成和减少出血风险的优势，并从环氧化酶-血栓素/前列环素和ADP-PI3K/Akt两个抗血小板关键通路，研究益气活血配伍合用双抗发挥双向作用的细胞分子机理，以为益气活血配伍联合双抗干预心脑血管血栓性疾病的临床应用提供实验依据。这对提高中医药心脑血管疾病二级预防疗效，具有重大意义。

Supplementing qi and activating blood circulation (SQAB) is a commonly used method for the treatment of cardiovascular and cerebrovascular thrombotic diseases in clinical practice of traditional Chinese medicine (TCM). Anti-thrombosis without increasing the risk of bleeding is the purpose of the treatment of these diseases. However, there are no evidence on whether TCM for SQAB combining with dual-antiplatelet drugs (aspirin, clopidogrel) could further improve the antithrombotic effect and reduce the risk of bleeding. In the present study, the experimental rat model with carotid artery thrombosis (focal cerebral ischemia model) or myocardial infarction, and endothelial injury model induced by lipid oxidation and platelet activation will be established to test the advantage of combining treatment on anti-thrombosis without increasing of bleeding, and to explore the multi-directional molecular mechanism through cyclooxygenase- prostacyclin and ADP-PI3K/Akt, which were well known as the key pathway of the thrombosis or bleeding. Therefore, this study will provide a experimental foundation to support the clinical application of TCM for SQAB combining with dual-antiplatelet drugs, which will be significant to improve the secondary prevention of cardiovascular and cerebrovascular diseases with TCM.